Short‐term (1 week) percentage change (improvement) in overall speech production · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Short‐term (1 week) change in isolated movement, objective and subjective measures of speech production SARA. Scale from: 0 to 6. Higher scores indicate more severe speech disorder. · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Short‐term (within 1 month) change in quality of life scores related to communication as measured by validated communication assessments · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Longer‐term (minimum 1 month) change in generic quality of life scores · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Adverse effects (during study) · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Longer‐term burdens (minimum 1 month) (for example, demands on caregivers, frequency of tests, restrictions on lifestyle) · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Economic outcomes · people with speech disorder resulting from hereditary ataxias
1 finding from 1 review
Number of responders · IBD patients
It is very uncertain whether IM erythropoietin changes number of responders ‐ active disease (12 weeks) compared with oral placebo (very low certainty).
1 finding from 1 review
Serious adverse events · IBD patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death · patients with anemia in people with AIDS
It is very uncertain whether recombinant Human Erythropoietin changes death compared with placebo (very low certainty).
1 finding from 1 review
Number of responders ‐ disease activity not stated (12 weeks) · IBD patients
IM erythropoietin + IV iron sucrose showed no clear difference in number of responders ‐ disease activity not stated (12 weeks) compared with IV iron sucrose + IM placebo (low certainty).
1 finding from 1 review
Serious adverse events ‐ disease activity not stated (12 weeks) · IBD patients
1 finding from 1 review
Maternal death · women with postpartum iron deficiency anaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Fatigue ‐ not reported · women with postpartum iron deficiency anaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Thromboembolic events ‐ not reported · women with postpartum iron deficiency anaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Persistent anaemia symptoms ‐ not reported · women with postpartum iron deficiency anaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · anemia in patients with rheumatoid arthritis
1 finding from 1 review
Hemoglobin (Hb) level at the end of the study · anemia in patients with rheumatoid arthritis
1 finding from 1 review
Fatigue ‐ not reported · anemia in patients with rheumatoid arthritis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events and drug reactions · anemia in patients with rheumatoid arthritis
1 finding from 1 review
no estimate extracted
1 study · 3 participants
Very low